



IPW

PATENT  
Customer No. 22,852  
Attorney Docket No. 09707.0001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
)  
Kazuo UMEZAWA *et al.* ) Group Art Unit: 1614  
)  
Application No.: 10/519,162 ) Examiner: Michael J Teale  
)  
Filed: August 15, 2005 ) Confirmation No.: 4831  
)  
For: DRUG COMPOSITION CONTAINING )  
NF-κB INHIBITOR )

**Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

Sir:

**SUPPLEMENTAL RESPONSE TO RESTRICTION REQUIREMENT**

Further to the Response filed on April 10, 2008, Applicants respectfully request reconsideration of this application in view of the following additional remarks. This supplemental response is being filed to further indicate which claims are readable upon the elected species.

As the Response filed on April 10, 2008, was a timely filed response to the restriction requirement of December 13, 2007, no extension of time is needed to have this Supplemental Response entered into the record and considered by the Examiner.

In the April 10<sup>th</sup> Response, Applicants elected, without traverse, to prosecute Group I, claims 1-12 and 20.

For species election, Applicants elected hydrogen for R1 and (A) for R2 (see claim 1) for a type of compound, and further elected "tumor metastasis" as the type of tumor (see claim 5).

Applicants submit that claims 1-12 and 20 read on the two elected species.

Upon finding the elected species patentable, Applicants respectfully request that the Office extend its search to the non-elected species.

Please grant any extensions of time required to enter this response and charge any additional required fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: April 11, 2008

By: David W. Hill  
David W. Hill  
Reg. No. 28,220  
(571) 203-2700